<DOC>
	<DOC>NCT00565630</DOC>
	<brief_summary>The purpose of the study is to confirm that Vigamox reaches similar aqueous concentration when administered as the commercially available eye drops or as a spray delivered from a proprietary device.</brief_summary>
	<brief_title>Using Device Delivering Ophthalmic Solution in a Spray Form Instead of Eye Drops</brief_title>
	<detailed_description>Patients scheduled for elective cataract surgery, will be randomly allocated to receive Vigamox 4 times , 1 hour prior to surgery, either via the experimental device in a spray form, or via the regular, commercially available bottle. Aqueous sample will be collected and submitted to a masked laboratory for measuring Vigamox concentration.</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients scheduled for elective cataract surgery Known allergy to quinolone compounds</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>